Qualified Digital Announces Acquisition of Xpediant Digital to Transform Pharma and Life Sciences Content and Data Operations
Qualified Digital (QD), a leading full-service digital business and experience agency, has announced its acquisition of Xpediant Digital, a premier provider of content supply chain automations for Pharma and Life Sciences as a services and product partner. Through its innovative and integrated product, built natively into Adobe Experience Manager and Veeva, Xpediant and its solutions transform the regulatory process for its customers creating an incredible return on time and costs. With over two decades of delivering high quality services and innovative products to solve some of the greatest challenges in highly regulated industries such as Pharma and Medtech, Xpediant expands Qualified Digital's focus on quality and high business impact within the Healthcare industry. With Qualified Digital's strategically led practice spanning the entire Adobe Experience Cloud, notably its rapidly expanding Adobe AEP and Workfront practices, the newly combined capabilities, and powerful talent, stand to truly disrupt the pharmaceutical and life sciences industry go-to-market process.
Said Jaqueline Saleem, CEO, Qualified Digital: 'We are beyond thrilled to welcome Xpediant to the QD family, expanding our collective capabilities to our existing and future customers. We are excited to hit the ground running, transforming content operations including MLR (Medical Legal Regulatory), while elevating digital experiences through consumer-led experience design and ecosystem orchestration. As the experience economy continues to realize the importance of end-to-end service providers who not only understand each standalone solution, but can execute on the vision and promise of orchestrating those connections to multiply the value they bring, our ethos only becomes stronger and ever more essential. The ability to automate and deliver truly multi-channel experiences from IVA, banner ads, email, SMS, web experiences and more has actually been made accessible to these brands in ways that have previously been arduous to attain. This acquisition doubles down on QD's commitment to accomplish ROI for our customers from both cost reduction and, even more so, revenue generating returns.'
Added Qusai Mahesri, CEO, Xpediant Digital, 'With content creation demands growing exponentially, Pharma organizations need smarter, more efficient solutions. Joining the Qualified Digital family allows us to deliver an integrated approach that optimizes the entire content lifecycle— from strategy and development to compliance and deployment. Customers have realized both months of time and millions in cost savings within a year of adopting Xpediant's XpConnect ® platform and elite services.'
Xpediant's clients include life science powerhouses Novo Nordisk, Fresenius, Bristol Myers Squibb, AstraZeneca and Zimmer Biomet.
QD serves clients in various industries, including CommonSpirit Health, Cigna, Mercy Health, CVS Health, Kaiser Permanente, Hitachi Vantara, and Rubrik.
The acquisition of Xpediant represents QD's first major expansion since partnering with Stella Point Capital, who invested in QD in 2024 to help scale its long term vision for expansion and growth.
About Qualified Digital
Qualified Digital (QD) is a leading full-service digital consultancy agency, specializing in customer experience and digital transformation. Founded in 2017 by CEO Jaqi Saleem, QD leverages its expertise in B2B and B2C business and marketing, prioritizing strategy in customer experience, data, content, and technology. Qualified Digital aims to deliver true customer journey orchestration, automation, and personalization, enabling you and your organization to drive meaningful experiences together.
With a strategic focus on Fortune 500+ companies, and specializations across healthcare and the complexities of B2B marketing life cycles, QD is dedicated to cultivating long-term relationships that drive unmatched customer experience and digital return on investment by keeping a close pulse on a brand's needs and opportunities. Learn more at www.qualifiedigital.com.
About Xpediant Digital
Xpediant Digital is a leading provider of content supply chain automation solutions, helping organizations streamline content creation, compliance, and delivery across multiple channels. With proprietary solutions that integrate seamlessly with leading content management and regulatory platforms, Xpediant Digital enables faster approvals, improved efficiency, and greater content reusability for life sciences and pharmaceutical companies. By leveraging AI-driven automation, intelligent workflows, and best-in-class integration technologies, Xpediant Digital empowers organizations to enhance content velocity and ensure compliance in a complex regulatory landscape. Learn more at www.xpediantdigital.com.
About Stella Point Capital
Stella Point Capital, a New York-based private equity firm, partners with founders, families and management teams of services businesses, including tech-enabled financial, consumer and marketing companies. The firm seeks investment opportunities with sellers who seek a value-added partner and often choose to retain equity stakes in their businesses. Founded by Justin Wender and Adam Godfrey, Stella Point focuses on well-positioned businesses with strong cultural foundations across North America. With over $500 million of equity invested across eight platform investments and eleven add-on acquisitions, Stella Point delivers operational expertise and senior counsel to achieve accelerated growth and build long-term value for its partners. For more information, please visit stellapoint.com.
SOURCE: Qualified Digital
Copyright Business Wire 2025.
PUB: 03/17/2025 08:00 AM/DISC: 03/17/2025 08:00 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29-07-2025
- Business Wire
Novotech Awarded Veeva Hero Award at 2025 Veeva R&D and Quality Summit
SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO), is proud to announce that we have received the highly regarded Veeva Hero award presented at the 2025 Veeva R&D and Quality Summit in Seoul, South Korea. Novotech, a globally recognized full-service clinical research organization (CRO), is proud to announce that we have received the highly regarded Veeva Hero award presented at the 2025 Veeva R&D and Quality Summit in Seoul, South Korea. Share Each year, Veeva recognizes industry-leading companies and organizations driving transformational change and growth as "Veeva Heroes." This year, Novotech was recognized for its early and proactive adoption of Veeva platforms to streamline global clinical trials through strong collaboration across sponsors, CRO, and trial sites accelerating drug development and reinforcing its evolution from a regional leader to a global player. 'This recognition was made possible thanks to the dedication and hard work of our cross-functional internal Veeva team, whose efforts were instrumental in achieving this milestone,' stated Dr. Yooni Kim, Managing Director, Asia-Pacific. 'Their commitment and collaborative spirit exemplify the core values that drive our success.' The strategic collaboration between has significantly contributed to mutual growth in the Korean market, enabling biotech and pharma sponsors to accelerate product development and expedite the delivery of innovative therapies to patients. Novotech remains committed to advancing this partnership fostering innovation and driving excellence in clinical research. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
Yahoo
25-07-2025
- Yahoo
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
Veeva Systems VEEV is entering a pivotal phase as it gradually transitions away from Salesforce's infrastructure, aiming to complete the shift by the end of September 2025. This move marks a significant step toward full platform independence, allowing Veeva to operate entirely on its proprietary Vault architecture. The strategy is designed to give Veeva greater control over product development, performance, and long-term innovation — especially as the company deepens its focus on delivering purpose-built software for the life sciences sector. Early signs are promising, with many clients already reporting smoother integration and more consistent performance on Vault. Veeva's recent performance shows just how central the Vault platform has become to its long-term growth story. Veeva has also been proactive in helping its Commercial Cloud customers prepare for the shift, offering migration roadmaps and hands-on support to ease the transition. While increased investment in R&D and customer onboarding may weigh on margins in the short term, Veeva appears focused on the bigger picture, owning its infrastructure to drive faster innovation and long-term differentiation in a highly specialized market. Peers Update For Salesforce CRM, the conclusion of its infrastructure partnership with Veeva marks a natural evolution as both companies refine their long-term strategies. While Veeva was a high-profile example of Salesforce's presence in life sciences, its shift reflects a broader industry trend toward purpose-built platforms. Salesforce continues to expand its healthcare and life sciences offerings through initiatives like Health Cloud and Data Cloud, aiming to meet the growing demand for tailored solutions. Although adoption varies across segments, Salesforce remains a key player with a broad enterprise footprint and a strong innovation pipeline. IQVIA IQV, a major player in the life sciences technology space, continues to compete through its deep data assets and broad service offerings. While its technology stack is not as tightly integrated as Veeva's, IQVIA's scale and diversified model give it a different kind of competitive edge. As Veeva builds out its post-Salesforce identity, IQVIA remains a key peer to watch — particularly in areas where data services and real-world evidence intersect with software. Veeva Systems' Price Performance, Valuation and Estimates Shares of VEEV have gained 36% in the year-to-date period compared with the industry's growth of 8.2%. Image Source: Zacks Investment Research From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.3, above the industry average. VEEV carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings implies a 15.8% rise from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Salesforce Inc. (CRM) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Digital Trends
09-07-2025
- Digital Trends
Our ‘best TV' is on sale for Prime Day — 65-inch Sony A95L QD-OLED at 17% off
TVs are among the most popular products to buy during Amazon's Prime Day, and if you're planning to get one, make it the 65-inch Sony A95L QD-OLED 4K TV. From its original price of $3,500, it's 17% off to $2,898, which is just several dollars higher than its lowest price ever. Even with the savings of $602, it's still a pretty significant investment, but it's a purchase that you'll never regret if you want an upgrade to your home theater setup. You're going to have to be quick in completing your transaction though, as we're not sure if the offer will remain available until the final minutes of the shopping event. Why you should buy the 65-inch Sony A95L QD-OLED 4K TV The Sony A95L QD-OLED 4K TV received a rare perfect score of 5 stars out of 5 stars in our review, making it worthy of our description as the 'best overall TV' in our roundup of the best TVs. The QD-OLED technology in its 65-inch screen combines QLED and OLED for fantastic color accuracy and brightness, as well as amazing contrast and luminance. The TV's Dolby Vision support and impressive speakers will create a cinematic experience within the comfort of your own living room, and 4K upscaling will improve the quality of everything that you watch. Since it's made by Sony, it's not a surprise that the Sony A95L QD-OLED 4K TV comes with exclusive features for the PlayStation 5, namely Auto HDR Tone Mapping and Auto Genre Picture Mode, for an even better visual experience when playing the best PS5 games. The TV is also perfect for watching streaming shows, as it has access to all of the popular streaming services through the Google TV platform that also grants access to Google Assistant for voice commands. In one of the most attractive TV deals that you can shop for Prime Day, the 65-inch Sony A95L QD-OLED 4K TV is on sale at 17% off for a discounted price of $2,898 from $3,500. You wouldn't want to miss this chance at savings of $602 when buying our favorite TV, which means you need to hurry with your purchase. Add the 65-inch Sony A95L QD-OLED 4K TV to your cart and finish the checkout process as soon as you can, to make sure that you get this amazing screen for almost its lowest-ever price.
